Zhang H, Song Y, Yang H, Liu Z, Gao L, Liang X, et al. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis. Oncogene. 2018;37:2456-2468 pubmed publisher

Zhu H, Zhang L, Wu Y, Dong B, Guo W, Wang M, et al. T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. elife. 2018;7: pubmed publisher

Sade Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175:998-1013.e20 pubmed publisher

Splitt S, Souza S, Valentine K, Castellanos B, Curd A, Hoyer K, et al. PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii. Infect Immun. 2018;86: pubmed publisher

Liu J, Wu L, Yang L, Deng W, Mao L, Wu H, et al. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J Exp Clin Cancer Res. 2018;37:44 pubmed publisher

Teigler J, Zelinskyy G, Eller M, Bolton D, Marovich M, Gordon A, et al. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. J Virol. 2017;91: pubmed publisher

Vazquez Mateo C, Collins J, Fleury M, Dooms H. Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7R? antibodies in NOD mice. BMC Immunol. 2017;18:18 pubmed publisher

Kurtulus S, Sakuishi K, Ngiow S, Joller N, Tan D, Teng M, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053-62 pubmed publisher

Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher

Tripathi S, Chabtini L, Dakle P, Smith B, Akiba H, Yagita H, et al. Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells. PLoS ONE. 2015;10:e0123439 pubmed publisher

Erickson J, Rogers M, Hastings A, Tollefson S, Williams J. Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol. 2014;193:5108-17 pubmed publisher

Mittal D, Young A, Stannard K, Yong M, Teng M, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74:3652-8 pubmed publisher

Dolina J, Braciale T, Hahn Y. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology. 2014;59:1351-65 pubmed publisher

Dietze K, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013;9:e1003798 pubmed publisher

McGray A, Hallett R, Bernard D, Swift S, Zhu Z, Teoderascu F, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22:206-18 pubmed publisher

Zelinskyy G, Myers L, Dietze K, Gibbert K, Roggendorf M, Liu J, et al. Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol. 2011;187:3730-7 pubmed publisher